MELANOMA (SKIN CANCER)

This trial is testing whether adding two new oral drugs, AMXT 1501 and DFMO, to standard cancer treatments can help control advanced breast cancer or melanoma that has worsened after prior therapies. The study will first find a safe dose and then see how well the combination work…

This study is testing a personalized cell therapy called lifileucel for people with advanced melanoma that has worsened after standard immunotherapy. Doctors take a patient's own tumor-fighting immune cells, grow large numbers of them in a lab, and then infuse them back into the …

This study is testing a new type of immune cell therapy called EBNK-001 for people with advanced solid tumors that have stopped responding to standard treatments. Participants receive 'off-the-shelf' natural killer (NK) cells from a donor after a short course of chemotherapy, wit…

This study is testing if giving a single dose of the immunotherapy drug pembrolizumab six weeks before surgery can help the body's immune system attack high-risk melanoma cells that might be too small to see on scans. It involves 49 adults with high-risk melanoma that hasn't visi…

This study is testing a new type of cell therapy for people with advanced solid tumors that have stopped responding to standard treatments. Doctors will analyze a patient's tumor to select a specific target, then infuse specially engineered immune cells (CAR-NK cells) from a heal…

This is a first-in-human study to find a safe dose and see how well a new drug called TGI-5 works, both by itself and combined with an existing immunotherapy (nivolumab). It is for adults with advanced solid tumors (like lung, colon, skin, or liver cancer) that have spread and no…

This early-stage study is testing the safety and best dose of a two-drug combination (alpelisib and pembrolizumab) for patients with advanced breast cancer or melanoma that has spread. It aims to see if this combo can help control the disease, including in cases where cancer has …

This study is testing a new oral drug, LNS8801, for people with advanced melanoma that has spread and no longer responds to standard immunotherapies. Researchers want to see if LNS8801, taken alone or combined with the drug pembrolizumab, can stop or slow cancer growth better tha…

This study is testing if giving a single dose of an immunotherapy drug called pembrolizumab before surgery can help shrink or eliminate thick melanoma tumors. It will involve about 30 adults with stage IIb/c melanoma who are already scheduled for surgery. Patients will receive ei…

This study aims to improve early detection of melanoma skin cancer by comparing two advanced diagnostic tools. Researchers will use a special non-invasive skin microscope (RCM) to examine suspicious moles before they are surgically removed, then analyze the tissue's genetic patte…

This study aims to improve how we predict who might get cancer and detect its return very early, before symptoms or scans show it. Researchers will analyze blood and tissue samples from 850 people with breast, ovarian, colorectal, lung, or skin cancer. The goal is to find genetic…

This study collects tumor tissue samples from cancer patients to research whether laboratory tests can predict which patients will respond to immunotherapy drugs. Researchers will analyze how live tumor samples react to immunotherapy treatments in the lab, then compare those resu…

This study aims to understand how a common type of melanoma immunotherapy might affect reproductive health and hormone levels in young adults. It will observe 80 men and premenopausal women with melanoma who are starting this treatment. Participants will answer questionnaires and…

This study aims to find blood markers that might help predict how skin cancer will progress and respond to treatment. Researchers will collect blood samples from 20 adults with melanoma or other skin cancers who are undergoing regular treatment. The goal is to see if certain subs…